Establishment and characterization of models of chemotherapy resistance in colorectal cancer: towards a predictive signature of chemoresistance

Research output: Contribution to journalJournal articlepeer-review

Standard

Establishment and characterization of models of chemotherapy resistance in colorectal cancer : towards a predictive signature of chemoresistance. / Jensen, Niels Frank; Stenvang, Jan; Beck, Mette K.; Hanáková, Barbora; Belling, Kirstine Christensen; Do, Khoa N.; Viuff, Birgitte Martine; Nygård, Sune Boris; Gupta, Ramneek; Rasmussen, Mads Heilskov; Tarpgaard, Line S.; Hansen, Tine P.; Budinská, Eva; Pfeiffer, Per; Bosman, Fred; Tejpar, Sabine; Roth, Arnaud; Delorenzi, Mauro; Andersen, Claus Lindbjerg; Rømer, Maria Unni Koefoed; Brünner, Nils; Moreira, José.

In: Molecular Oncology, Vol. 9, No. 6, 24.02.2015, p. 1169-1185.

Research output: Contribution to journalJournal articlepeer-review

Harvard

Jensen, NF, Stenvang, J, Beck, MK, Hanáková, B, Belling, KC, Do, KN, Viuff, BM, Nygård, SB, Gupta, R, Rasmussen, MH, Tarpgaard, LS, Hansen, TP, Budinská, E, Pfeiffer, P, Bosman, F, Tejpar, S, Roth, A, Delorenzi, M, Andersen, CL, Rømer, MUK, Brünner, N & Moreira, J 2015, 'Establishment and characterization of models of chemotherapy resistance in colorectal cancer: towards a predictive signature of chemoresistance', Molecular Oncology, vol. 9, no. 6, pp. 1169-1185. https://doi.org/10.1016/j.molonc.2015.02.008

APA

Jensen, N. F., Stenvang, J., Beck, M. K., Hanáková, B., Belling, K. C., Do, K. N., Viuff, B. M., Nygård, S. B., Gupta, R., Rasmussen, M. H., Tarpgaard, L. S., Hansen, T. P., Budinská, E., Pfeiffer, P., Bosman, F., Tejpar, S., Roth, A., Delorenzi, M., Andersen, C. L., ... Moreira, J. (2015). Establishment and characterization of models of chemotherapy resistance in colorectal cancer: towards a predictive signature of chemoresistance. Molecular Oncology, 9(6), 1169-1185. https://doi.org/10.1016/j.molonc.2015.02.008

Vancouver

Jensen NF, Stenvang J, Beck MK, Hanáková B, Belling KC, Do KN et al. Establishment and characterization of models of chemotherapy resistance in colorectal cancer: towards a predictive signature of chemoresistance. Molecular Oncology. 2015 Feb 24;9(6):1169-1185. https://doi.org/10.1016/j.molonc.2015.02.008

Author

Jensen, Niels Frank ; Stenvang, Jan ; Beck, Mette K. ; Hanáková, Barbora ; Belling, Kirstine Christensen ; Do, Khoa N. ; Viuff, Birgitte Martine ; Nygård, Sune Boris ; Gupta, Ramneek ; Rasmussen, Mads Heilskov ; Tarpgaard, Line S. ; Hansen, Tine P. ; Budinská, Eva ; Pfeiffer, Per ; Bosman, Fred ; Tejpar, Sabine ; Roth, Arnaud ; Delorenzi, Mauro ; Andersen, Claus Lindbjerg ; Rømer, Maria Unni Koefoed ; Brünner, Nils ; Moreira, José. / Establishment and characterization of models of chemotherapy resistance in colorectal cancer : towards a predictive signature of chemoresistance. In: Molecular Oncology. 2015 ; Vol. 9, No. 6. pp. 1169-1185.

Bibtex

@article{c27a8d3bc53b46b98f9b1efdde64aa8a,
title = "Establishment and characterization of models of chemotherapy resistance in colorectal cancer: towards a predictive signature of chemoresistance",
abstract = "Current standard treatments for metastatic colorectal cancer (CRC) are based on combination regimens with one of the two chemotherapeutic drugs, irinotecan or oxaliplatin. However, drug resistance frequently limits the clinical efficacy of these therapies. In order to gain new insights into mechanisms associated with chemoresistance, and departing from three distinct CRC cell models, we generated a panel of human colorectal cancer cell lines with acquired resistance to either oxaliplatin or irinotecan. We characterized the resistant cell line variants with regards to their drug resistance profile and transcriptome, and matched our results with datasets generated from relevant clinical material to derive putative resistance biomarkers. We found that the chemoresistant cell line variants had distinctive irinotecan- or oxaliplatin-specific resistance profiles, with non-reciprocal cross-resistance. Furthermore, we could identify several new, as well as some previously described, drug resistance-associated genes for each resistant cell line variant. Each chemoresistant cell line variant acquired a unique set of changes that may represent distinct functional subtypes of chemotherapy resistance. In addition, and given the potential implications for selection of subsequent treatment, we also performed an exploratory analysis, in relevant patient cohorts, of the predictive value of each of the specific genes identified in our cellular models.",
author = "Jensen, {Niels Frank} and Jan Stenvang and Beck, {Mette K.} and Barbora Han{\'a}kov{\'a} and Belling, {Kirstine Christensen} and Do, {Khoa N.} and Viuff, {Birgitte Martine} and Nyg{\aa}rd, {Sune Boris} and Ramneek Gupta and Rasmussen, {Mads Heilskov} and Tarpgaard, {Line S.} and Hansen, {Tine P.} and Eva Budinsk{\'a} and Per Pfeiffer and Fred Bosman and Sabine Tejpar and Arnaud Roth and Mauro Delorenzi and Andersen, {Claus Lindbjerg} and R{\o}mer, {Maria Unni Koefoed} and Nils Br{\"u}nner and Jos{\'e} Moreira",
note = "Copyright {\textcopyright} 2015 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.",
year = "2015",
month = feb,
day = "24",
doi = "10.1016/j.molonc.2015.02.008",
language = "English",
volume = "9",
pages = "1169--1185",
journal = "Molecular Oncology",
issn = "1574-7891",
publisher = "Elsevier",
number = "6",

}

RIS

TY - JOUR

T1 - Establishment and characterization of models of chemotherapy resistance in colorectal cancer

T2 - towards a predictive signature of chemoresistance

AU - Jensen, Niels Frank

AU - Stenvang, Jan

AU - Beck, Mette K.

AU - Hanáková, Barbora

AU - Belling, Kirstine Christensen

AU - Do, Khoa N.

AU - Viuff, Birgitte Martine

AU - Nygård, Sune Boris

AU - Gupta, Ramneek

AU - Rasmussen, Mads Heilskov

AU - Tarpgaard, Line S.

AU - Hansen, Tine P.

AU - Budinská, Eva

AU - Pfeiffer, Per

AU - Bosman, Fred

AU - Tejpar, Sabine

AU - Roth, Arnaud

AU - Delorenzi, Mauro

AU - Andersen, Claus Lindbjerg

AU - Rømer, Maria Unni Koefoed

AU - Brünner, Nils

AU - Moreira, José

N1 - Copyright © 2015 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.

PY - 2015/2/24

Y1 - 2015/2/24

N2 - Current standard treatments for metastatic colorectal cancer (CRC) are based on combination regimens with one of the two chemotherapeutic drugs, irinotecan or oxaliplatin. However, drug resistance frequently limits the clinical efficacy of these therapies. In order to gain new insights into mechanisms associated with chemoresistance, and departing from three distinct CRC cell models, we generated a panel of human colorectal cancer cell lines with acquired resistance to either oxaliplatin or irinotecan. We characterized the resistant cell line variants with regards to their drug resistance profile and transcriptome, and matched our results with datasets generated from relevant clinical material to derive putative resistance biomarkers. We found that the chemoresistant cell line variants had distinctive irinotecan- or oxaliplatin-specific resistance profiles, with non-reciprocal cross-resistance. Furthermore, we could identify several new, as well as some previously described, drug resistance-associated genes for each resistant cell line variant. Each chemoresistant cell line variant acquired a unique set of changes that may represent distinct functional subtypes of chemotherapy resistance. In addition, and given the potential implications for selection of subsequent treatment, we also performed an exploratory analysis, in relevant patient cohorts, of the predictive value of each of the specific genes identified in our cellular models.

AB - Current standard treatments for metastatic colorectal cancer (CRC) are based on combination regimens with one of the two chemotherapeutic drugs, irinotecan or oxaliplatin. However, drug resistance frequently limits the clinical efficacy of these therapies. In order to gain new insights into mechanisms associated with chemoresistance, and departing from three distinct CRC cell models, we generated a panel of human colorectal cancer cell lines with acquired resistance to either oxaliplatin or irinotecan. We characterized the resistant cell line variants with regards to their drug resistance profile and transcriptome, and matched our results with datasets generated from relevant clinical material to derive putative resistance biomarkers. We found that the chemoresistant cell line variants had distinctive irinotecan- or oxaliplatin-specific resistance profiles, with non-reciprocal cross-resistance. Furthermore, we could identify several new, as well as some previously described, drug resistance-associated genes for each resistant cell line variant. Each chemoresistant cell line variant acquired a unique set of changes that may represent distinct functional subtypes of chemotherapy resistance. In addition, and given the potential implications for selection of subsequent treatment, we also performed an exploratory analysis, in relevant patient cohorts, of the predictive value of each of the specific genes identified in our cellular models.

U2 - 10.1016/j.molonc.2015.02.008

DO - 10.1016/j.molonc.2015.02.008

M3 - Journal article

C2 - 25759163

VL - 9

SP - 1169

EP - 1185

JO - Molecular Oncology

JF - Molecular Oncology

SN - 1574-7891

IS - 6

ER -

ID: 135227760